PT  - JOURNAL ARTICLE
AU  - P Ziober-Malinowska
AU  - M Bobinski
AU  - K Barszczewska
AU  - K Fraszczak
AU  - J Kotarski
AU  - R Tarkowski
TI  - EP1042 Evaluation of PCTAIRE2 kinase expression in ovarian cancer and ovaries and fallopian tubes with BRCA1 mutation
AID  - 10.1136/ijgc-2019-ESGO.1085
DP  - 2019 Nov 01
TA  - International Journal of Gynecologic Cancer
PG  - A552--A552
VI  - 29
IP  - Suppl 4
4099  - http://ijgc.bmj.com/content/29/Suppl_4/A552.1.short
4100  - http://ijgc.bmj.com/content/29/Suppl_4/A552.1.full
SO  - Int J Gynecol Cancer2019 Nov 01; 29
AB  - Introduction/Background Ovarian cancer in about 10% is an inherited cancer. The BRCA1 gene and/or the BRCA2 gene play a role not only in breast cancer but also in ovarian cancer. Cyclin-dependent kinases regulate the cell cycle by activating the phosphorylation (activation) reaction. They combine with proteins in complexes regulating the passage of cells into individual phases of the cycle. An interesting group of kinases is the PCTAIRE family of kinases, consisting of PCTAIRE1 (CDK16 / PCTK1 / PCT1), PCTAIRE2 (CDK / PCTK2 / PCT2) and PCTAIRE3 (CDK18 / PCTK3 / PCT3). Their common feature is the protection of the amino acid sequence of PCTAIRE in the helical alpha-C region of kinase binding to related cyclins.Methodology The study included 88 patients operated on in the 1st Department of Oncological Gynecology and Gynecology of the Medical University in Lublin (41 patients with ovarian cancer, 13 ovaries prophylactically removed in patients with confirmed the BRCA1 gene mutation and 21 normal ovaries of patients operated on due to other non-neoplastic diseases. Immunohistochemistry was performed using a PCTAIRE2 IgG polyclonal rabbit antibody from Bethyl Laboratories, USA. Paraffin sections after H+E staining were evaluated under a microscope and evaluated for the intensity of the abscess (0 - no expression, 1 - weak, 2 - medium, 3 - strong expression). The final result was the average of the three readings obtained.Results Higher PCTAIRE2 expression was obtained in patients with a higher degree of disease (FIGO III and IV). A shorter survival time has been demonstrated in patients with elevated PCTAIRE2 expression.Conclusion Increased expression of the PCTAIRE2 nuclear kinase may be responsible for adverse disease course and worse prognosis of patients with ovarian cancer.Disclosure Nothing to disclose